Published in JAMA Ophthalmolog y on 3 July 2024 Abstract Importance Anecdotal experience raised the possibility that semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA) with rapidly increasing use, is associated with nonarteritic anterior ischaemic optic neuropathy (NAION)
While a wide range of pharmacological treatments and disease management regimens exist to treat these conditions with varying degrees of efficacy, a promising new drug class known as glucagon-like peptide 1 receptor agonists (GLP-1s) and combination incretins such as dual GLP-1/glucosedependent insulinotropic polypeptides (GLP-1/GIPs, a subcategory of GLP-1s) has attracted widespread attention and interest from providers and patients for its potential to treat both these and adjacent conditions, and especially to drive weight loss
Achieving this dosage should be a gradual process, typically over several weeks, to ensure your comfort and safety
The present article demonstrates the association of six injectable active substances that are effective to treat facial fat
That matters because someone may feel that retatrutide is "working" before a large body-weight change appears
:max_bytes(150000):strip_icc()/Common-Symptoms-From-Taking-a-GLP-1-And-How-to-Manage-Them-9e5bb7cee0484522a50dd9d7ce954cc4.jpg)
